400 completed, 84 terminated, 78 recruiting, 55 unknown. 374 Phase 2, 249 Phase 1, 86 Phase 4, 84 Phase 3, 28 Not applicable.
Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption Baricitinib 2 MG, Sirolimus 2 MG, Placebo of baricitinib 2 MG - HIV-1-infection | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 191 | 2027-05-01 | 2026-10-19 |
| Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH) | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 15 | 2027-01-01 | 2026-06-25 |
| Effects of Sirolimus on Asymptomatic ApoE4 Carriers Sirolimus (rapamycin), Placebo - Genetic Predisposition to Disease, Healthy Volunteer | Phase 1 | Recruiting | University of Missouri-Columbia | 225 | 2026-12-01 | 2026-10-05 |
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy | Phase 4 | Recruiting | Sarepta Therapeutics, Inc. | 20 | 2026-11-30 | 2026-11-12 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-18 | 2026-11-13 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-11-01 | 2026-09-24 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-11-01 | 2026-11-10 |
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM) | Phase 1 | Recruiting | Umoja Biopharma | 100 | 2026-11-01 | 2026-11-13 |
| Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Familial Platelet Disorder With Associated Myeloid Malignancy | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 6 | 2026-10-05 | 2026-10-13 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 40 | 2026-10-01 | 2026-09-09 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-10 | 2026-11-12 |
| Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis Rapamycin - Familial Adenomatous Polyposis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 25 | 2026-09-01 | 2026-05-08 |
| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma Sirolimus for injection (Albumin-bound) - Epithelioid Hemangioendothelioma | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2026-08-01 | 2026-07-06 |
| Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Domatinostat, Sirolimus - Sarcoma, Osteosarcoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 74 | 2026-07-15 | 2026-09-03 |
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
Showing 20 of 727. Sign in to see all of them.
Graft vs Host Disease (57) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Myelodysplastic Syndromes (36) · Leukemia, Myeloid, Acute (35) · Multiple Myeloma (31) · Lymphoma, Non-Hodgkin (30) · Hodgkin Disease (28) · Anemia, Sickle Cell (25) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Leukemia (24) · Lymphoma (24) · Diabetes Mellitus, Type 1 (21) · Hematologic Neoplasms (20) · Renal Insufficiency (19) · Lymphoma, Mantle-Cell (18)
National Cancer Institute (NCI) (77) · National Institute of Allergy and Infectious Diseases (NIAID) (30) · Wyeth is now a wholly owned subsidiary of Pfizer (25) · M.D. Anderson Cancer Center (14) · City of Hope Medical Center (13) · Mayo Clinic (13) · Dana-Farber Cancer Institute (12) · Fred Hutchinson Cancer Center (12) · Peking Union Medical College Hospital (10) · The University of Texas Health Science Center at San Antonio (10) · University of Chicago (10) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (9) · H. Lee Moffitt Cancer Center and Research Institute (8) · National Heart, Lung, and Blood Institute (NHLBI) (8) · Yale University (8)
United States (473) · China (57) · Canada (43) · France (28) · Germany (26) · Italy (26) · Spain (22) · Australia (19) · South Korea (17) · United Kingdom (14) · Netherlands (13) · Belgium (12) · Sweden (10) · Switzerland (10) · Austria (9)
Elizabeth M Kang, M.D. (7) · Christopher G Kanakry, M.D. (5) · Margaret Kasner, MD (5) · Ezra Cohen, MD (4) · Joel Naor, MD (4) · Amit Oza (3) · Andrew Posselt, MD, PhD (3) · Bernhard Hering, MD (3) · Brenda Sandmaier (3) · Camillo Ricordi, MD (3)
PMID 36240296, PMID 39356039, PMID 19192962, PMID 35030255, PMID 42133908, PMID 19208097, PMID 26504182, PMID 28486787, PMID 31489702, PMID 32014025, PMID 15302787, PMID 19670189, PMID 22871490, PMID 23438305, PMID 24363761, PMID 27881371, PMID 29654388, PMID 30270358, PMID 32499241, PMID 33580918, PMID 34082006, PMID 34273457, PMID 34524406, PMID 35254001, PMID 39831682, PMID 40010689, PMID 40107509, PMID 40132910, PMID 40197799, PMID 41114938, PMID 41871072, PMID 10028970, PMID 10030657, PMID 10199738, PMID 10213344, PMID 10221490, PMID 10556226, PMID 10594802, PMID 10598732, PMID 10798738, PMID 10802712, PMID 10830164, PMID 10952828, PMID 11055975, PMID 11057898, PMID 11250334, PMID 11514367, PMID 11803349, PMID 12088775, PMID 12176626
P30CA015704 (9), U10CA025224 (7), P30CA033572 (6), N01CM00071 (5), N01CM62201 (5), P30CA006973 (5), P30CA016672 (5), U10CA027469 (5), U10CA098543 (5), N01CM00038 (4), N01CM62202 (4), P01CA018029 (4), P30CA008748 (4), P30CA014599 (4), P30CA015083 (4)